Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Dabigatran Superior to Warfarin Regardless of Stroke Risk: BI
May 23, 2011
- Alfresa HD: Double-digit Decline in Profits Despite Higher Sales
May 23, 2011
- Tofacitinib for RA Meets Primary Endpoints in PIII: Pfizer
May 23, 2011
- Operating Profits Down 60% Due to Stalled Price Negotiations: Suzuken
May 23, 2011
- Fingolimod Reduced Risk of MS Disability Progression: Novartis
May 23, 2011
- Operating Profits Drop 46.6% Due to Tough Price Negotiations: Toho HD
May 23, 2011
- T-DM1 Significantly Extends PFS in HER2-Positive Metastatic Breast Cancer: Roche
May 23, 2011
- DSP's Development Policy to Focus on Specialty Areas in the US
May 23, 2011
- Results of Dabigatran Sub-Analysis Similar in Japanese Patients vs Overall Study Population
May 23, 2011
- First European Launch of Rivalo in Spain: Kowa
May 23, 2011
- 7 Diseases to Gain Importance in Next 10 Years: JHSF Report
May 23, 2011
- Sawai, Takeda Take Actos Patent Dispute to IP High Court
May 16, 2011
- Long-Acting ESA Mircera Approved: Chugai
May 16, 2011
- Korosho Invites Medical Societies to Present Views on 10 Switch OTC Drug Candidates
May 16, 2011
- DSP Licenses Novel Topical Analgesic to Maruho
May 16, 2011
- Glubes Approved for Type 2 Diabetes: Kissei
May 16, 2011
- Sato Pharm. Launches Switch OTC Version of Clotrimazole for Vaginal Candidiasis
May 16, 2011
- Takeda Announces Equity Investment in Fate Therapeutics of US
May 16, 2011
- Once-Daily Mirapex Approved for Parkinson's Disease: NBI
May 16, 2011
- Daiichi Sankyo to Launch AD Treatment MEMARY in June
May 16, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…